




Instance: composition-en-4e78538b495fe763304c16d92584575d
InstanceOf: CompositionUvEpi
Title: "Composition for eptifibatide Package Leaflet"
Description:  "Composition for eptifibatide Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6800cbc006aecb209b34dd0d22d9e8db)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - eptifibatide"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Eptifibatide Accord is and what it is used for </li>
<li>What you need to know before you are given Eptifibatide Accord </li>
<li>How to use Eptifibatide Accord </li>
<li>Possible side effects </li>
<li>How to store Eptifibatide Accord </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What eptifibatide is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What eptifibatide is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Eptifibatide Accord is an inhibitor of platelet aggregation. This means that it helps to prevent blood 
clots from forming.  </p>
<p>It is used in adults with manifestation of severe coronary insufficiency defined as spontaneous and 
recent chest pain with electrocardiographic abnormalities or biological changes. It is usually given 
with aspirin and unfractionated heparin. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take eptifibatide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take eptifibatide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Eptifibatide Accord:</p>
<ul>
<li>if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section 
6). </li>
<li>if you have recently had bleeding from your stomach, intestines, bladder or other organs, for 
example if you have seen abnormal blood in your stool or urine (except from menstrual bleeding) 
in the past 30 days. </li>
<li>if you have had a stroke within the past 30 days or any haemorrhagic stroke (also, be sure your 
doctor knows if you ever had a stroke). </li>
<li>if you have had a brain tumour or a condition that affects the blood vessels around the brain. </li>
<li>if you had a major operation or severe injury during the past 6 weeks. </li>
<li>if you have or have had bleeding problems. </li>
<li>if you have or have had difficulty with your blood clotting or a low blood platelet count. </li>
<li>if you have or have had severe hypertension (high blood pressure). </li>
<li>if you have or have had severe kidney or liver problems. </li>
<li>if you have been treated with another medicine of the same type as Eptifibatide Accord. </li>
</ul>
<p>Please tell your doctor if you have had any of these conditions. If you have any questions, ask your 
doctor or hospital pharmacist or nurse. </p>
<p>Warnings and precautions 
- Eptifibatide Accord is recommended for use only in adult, hospitalised patients in coronary care 
units. 
- Eptifibatide Accord is not intended for use in children or adolescents less than 18 years of age. 
Before and during your treatment with Eptifibatide Accord, samples of your blood will be tested as a 
safety measure to limit the possibility of unexpected bleeding. 
During use of Eptifibatide Accord, you will be checked carefully for any signs of unusual or 
unexpected bleeding. </p>
<p>Talk to your doctor or hospital pharmacist or nurse before using Eptifibatide Accord. </p>
<p>Other medicines and Eptifibatide Accord 
To avoid the possibility of interactions with other medicines please tell your doctor or hospital 
pharmacist or nurse if you are taking or have recently taken or might take any other medicines, 
including medicines obtained without a prescription. Particularly: blood thinners (oral anticoagulants) 
or medicines that prevent blood clots, including warfarin, dipyridamole, ticlopidine, aspirin (except 
those that you may be given as part of Eptifibatide Accord treatment).  </p>
<p>Pregnancy, breast-feeding and fertility 
Eptifibatide Accord is not usually recommended for use during pregnancy. Tell your doctor if you are 
pregnant, think you might be pregnant or are planning to have a baby. Your doctor will weigh up the 
benefit to you against the risk to your baby of using Eptifibatide Accord while you are pregnant. </p>
<p>If you are breast-feeding a baby, breast-feeding should be interrupted during the treatment period. </p>
<p>Eptifibatide Accord contains sodium 
This medicine contains 172 mg sodium (main component of cooking/table salt) in each vial. This is 
equivalent to 8.6% of the recommended maximum daily dietary intake of sodium for an adult.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take eptifibatide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take eptifibatide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Eptifibatide Accord is given into the vein by direct injection followed by an infusion (drip solution). 
The dose given is based on your weight. The recommended dose is 180 microgram/kg administered as 
a bolus (rapid intravenous injection), followed by an infusion (drip solution) of 
2 microgram/kg/minute for up to 72 hours. If you have kidney disease, the infusion dose may be 
reduced to 1 microgram/kg/minute. </p>
<p>If percutaneous coronary intervention (PCI) is performed during Eptifibatide Accord therapy, the 
intravenous solution may be continued for up to 96 hours. </p>
<p>You must also be given doses of aspirin and heparin (if not contraindicated in your case). </p>
<p>If you have any further questions on the use of this product, ask your doctor or hospital pharmacist or 
nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Very common side effects 
These may affect more than 1 in 10 people 
- minor or major bleeding, (for example, blood in urine, blood in stool, vomiting blood, or bleeding 
with surgical procedures). 
- anaemia (decreased number of red blood cells).  </p>
<p>Common side effects 
These may affect up to 1 in 10 people 
- inflammation of a vein. </p>
<p>Uncommon side effects 
These may affect up to 1 in 100 people 
- reduction in the number of platelets (blood cells necessary for blood clotting). 
- reduced blood flow to the brain. </p>
<p>Very rare side effects 
These may affect up to 1 in 10,000 people 
- serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the lungs). 
- fatal bleeding. 
- severe reduction in the number of platelets (blood cells necessary for blood clotting). 
- skin rash (such as hives). 
- sudden, severe allergic reaction. </p>
<p>If you notice any signs of bleeding, notify your doctor or hospital pharmacist or nurse immediately. 
Very rarely, bleeding has become severe and even fatal. Safety measures to prevent this from 
happening include blood tests and careful checking by the healthcare professionals taking care of you.  </p>
<p>If you develop severe allergic reaction or hives, notify your doctor or hospital pharmacist or nurse 
immediately. </p>
<p>Other events that may occur in patients, who require this type of treatment, include those that are 
related to the condition you are having treated, such as rapid or irregular heartbeat, low blood pressure, 
shock or cardiac arrest. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or hospital pharmacist or nurse. This includes any 
possible side effects not listed in this leaflet. You can also report side effects directly via the national 
reporting system listed in Appendix V. By reporting side effects you can help provide more 
information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store eptifibatide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store eptifibatide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children  </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the vial after (EXP). The 
expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C   8 C). </p>
<p>Keep the vial in the outer package in order to protect from light. However, protection of Eptifibatide 
Accord solution from light is not necessary during administration. </p>
<p>Before using, the vial contents should be inspected. 
Eptifibatide Accord should not be used if it is noticed that particulate matter or discoloration is present.  </p>
<p>Any unused medicine after opening should be thrown away.   </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your hospital pharmacist 
how to throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Eptifibatide Accord contains </p>
<p>The active substance is eptifibatide.<br />
Eptifibatide Accord 0.75 mg/ml: Each ml of solution for infusion contains 0.75 mg of 
eptifibatide. One vial of 100 ml of solution for infusion contains 75 mg of eptifibatide.  </p>
<p>The other ingredients are citric acid monohydrate, sodium hydroxide and water for injections. </p>
<p>What Eptifibatide Accord looks like and contents of the pack 
Eptifibatide Accord 0.75 mg/ml solution for infusion: 100 ml vial, pack of one vial.  </p>
<p>Eptifibatide Accord 0.75 mg/ml: The clear, colourless solution is contained in a 100 ml glass vial, 
which is closed with a butyl rubber stopper and sealed with a flip-off aluminium seal. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder: </p>
<p>Accord Healthcare S.L.U.<br />
World Trade Center, Moll de Barcelona, s/n,<br />
Edifici Est 6  planta,<br />
08039 Barcelona,<br />
Spain </p>
<p>Manufacturer: </p>
<p>Accord Healthcare Polska Sp.z o.o., 
ul. Lutomierska 50,95-200 Pabianice, Poland </p>
<p>This leaflet was last revised in &lt;{MM/YYYY}&gt;. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-4e78538b495fe763304c16d92584575d
InstanceOf: CompositionUvEpi
Title: "Composition for eptifibatide Package Leaflet"
Description:  "Composition for eptifibatide Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6800cbc006aecb209b34dd0d22d9e8db)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - eptifibatide"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at få Eptifibatide Accord 
3. Sådan får du Eptifibatide Accord 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What eptifibatide is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What eptifibatide is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Eptifibatide Accord hæmmer sammenklumpning af blodplader. Det betyder, at det hjælper med at 
forebygge blodpropper. </p>
<p>Det bruges til voksne med tegn på svær koronarinsufficiens defineret som spontane og nylige 
brystsmerter med unormale ændringer i elektrokardiogrammet eller biologiske forandringer. Det gives 
normalt sammen med acetylsalicylsyre og ufraktioneret heparin. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take eptifibatide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take eptifibatide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Eptifibatide Accord:</p>
<ul>
<li>hvis du er allergisk over for eptifibatid eller et af de øvrige indholdsstoffer i Eptifibatide Accord 
(angivet i punkt 6) </li>
<li>hvis du for nyligt har haft blødning fra mave, tarm, blære eller andre organer, fx hvis du har 
observeret unormalt blod i afføring eller urin (undtagen fra menstruationsblødning) i de seneste 
30 dage </li>
<li>hvis du har haft et slagtilfælde inden for de sidste 30 dage eller nogen form for hjerneblødning 
(husk også at fortælle lægen, hvis du nogensinde har haft et slagtilfælde) </li>
<li>hvis du har haft en hjernetumor eller en tilstand, der påvirker blodkarrene omkring hjernen </li>
<li>hvis du har gennemgået en større operation eller er blevet alvorligt skadet inden for de sidste 
6 uger </li>
<li>hvis du har eller har haft blødningsproblemer </li>
<li>hvis du har eller har haft besvær med størkning af blod eller et lavt antal blodplader </li>
<li>hvis du har eller har haft svær hypertension (forhøjet blodtryk) </li>
<li>hvis du har eller har haft alvorlige nyre- eller leversygdomme </li>
<li>hvis du er blevet behandlet med anden medicin af samme type som Eptifibatide Accord. </li>
</ul>
<p>Fortæl det til lægen, hvis du lider af en af disse tilstande. Kontakt lægen, apotekspersonalet eller 
sygeplejersken, hvis du har spørgsmål. </p>
<p>Advarsler og forsigtighedsregler 
- Eptifibatide Accord anbefales kun til anvendelse hos voksne patienter indlagt på hjerteafdeling. 
- Eptifibatide Accord er ikke beregnet til anvendelse hos børn eller unge under 18 år. 
- Før og under din behandling med Eptifibatide Accord, vil du få taget blodprøver, der skal 
undersøges, for at begrænse risikoen for en uventet blødning. 
- Under brugen af Eptifibatide Accord vil du blive omhyggeligt undersøgt for tegn på usædvanlig 
eller uventet blødning. </p>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, før du bruger Eptifibatide Accord. </p>
<p>Brug af anden medicin sammen med Eptifibatide Accord 
For at undgå interaktioner med anden medicin, skal du altid fortælle det til lægen eller 
sundhedspersonalet, hvis du bruger anden medicin eller har brugt det for nylig. Dette gælder også 
medicin, som ikke er købt på recept. Især:</p>
<ul>
<li>blodfortyndende medicin (orale antikoagulantia) </li>
<li>medicin, der forebygger blodpropper, herunder warfarin, dipyridamol, ticlopidin, acetylsalicylsyre 
(undtagen den medicin, du kan få som en del af behandlingen med Eptifibatide Accord). </li>
</ul>
<p>Graviditet, amning og frugtbarhed 
Eptifibatide Accord anbefales normalt ikke til brug under graviditet. Fortæl det til lægen, hvis du er 
gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid. Lægen vil opveje fordelene for 
dig ved at få Eptifibatide Accord, mens du er gravid, op mod risikoen for dit ufødte barn. </p>
<p>Hvis du ammer, bør amningen afbrydes i behandlingsperioden. </p>
<p>Eptifibatide Accord indeholder natrium 
Hvert hætteglas af dette lægemiddel indeholder 172 mg natrium (hovedkomponenten i 
bordsalt/madlavningssalt). Dette svarer til 8,6 % af det anbefalede maksimale daglige indtag af natrium 
for en voksen.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take eptifibatide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take eptifibatide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Eptifibatide Accord gives i en blodåre ved direkte injektion efterfulgt af infusion (drop). Den givne dosis 
er baseret på din vægt. Den sædvanlige dosis er 180 mikrogram/kg indgivet som bolus (hurtig intravenøs 
injektion), efterfulgt af infusion (drop) på 2 mikrogram/kg/minut i op til 72 timer. Hvis du har nedsat 
nyrefunktion, kan dosis blive nedsat til 1 mikrogram/kg/minut. </p>
<p>Hvis perkutan koronarintervention (PCI) foretages under behandlingen med Eptifibatide Accord, kan 
behandlingen fortsættes i indtil 96 timer. </p>
<p>Du skal også have acetylsalicylsyre og heparin (medmindre du ikke kan tåle disse). </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis du har spørgsmål til brugen af dette produkt. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Meget almindelige bivirkninger<br />
Dette kan forekomme hos flere end 1 ud af 10 patienter 
- større eller mindre blødning (fx blod i urin eller afføring, i opkast eller i forbindelse med 
operation) 
- blodmangel (nedsat antal røde blodlegemer). </p>
<p>Almindelige bivirkninger<br />
Dette kan forekomme hos op til 1 ud af 10 patienter 
- betændelse i en blodåre. </p>
<p>Ikke almindelige bivirkninger<br />
Dette kan forekomme hos op til 1 ud af 100 patienter 
- nedsat antal blodplader (celler, der får blodet til at størkne) 
- nedsat blodtilførsel til hjernen. </p>
<p>Meget sjældne bivirkninger<br />
Dette kan forekomme hos op til 1 ud af 10.000 patienter 
- alvorlig blødning (fx blødende mavesår, hjerneblødning, eller blødning i lungerne) 
- blødning med dødelig udgang 
- alvorligt nedsat antal blodplader (celler, der får blodet til at størkne) 
- kløende udslæt, såsom nældefeber 
- pludselig, alvorlig allergisk reaktion. </p>
<p>Hvis du bemærker nogen tegn på blødning, så kontakt straks lægen eller sundhedspersonalet. Blødning 
har i sjældne tilfælde vist sig at være meget alvorlig eller endog livstruende. De forholdsregler, der tages 
for at undgå blødning, inkluderer blodprøver og omhyggelige lægeundersøgelser.  </p>
<p>Hvis du får en alvorlig allergisk reaktion eller kløende udslæt, så kontakt straks lægen eller 
sundhedspersonalet. </p>
<p>Øvrige bivirkninger, der kan forekomme hos patienter, der har behov for denne slags behandling, er 
forbundet med den sygdom, du behandles for, såsom hurtigt eller uregelmæssigt hjerteslag, lavt blodtryk, 
shock eller hjertestop. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store eptifibatide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store eptifibatide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og hætteglasset efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C - 8 °C). </p>
<p>Opbevares i den originale yderpakning for at beskytte mod lys. Det er ikke nødvendigt at beskytte 
Eptifibatide Accord mod lys under behandlingen. </p>
<p>Inspicer indholdet af hætteglasset før brug. 
Brug ikke Eptifibatide Accord, hvis der er bundfald eller misfarvning. </p>
<p>Bortskaf al ikke anvendt lægemiddel efter åbning. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Eptifibatide Accord indeholder:</p>
<ul>
<li>Aktivt stof: eptifibatid. 
Eptifibatide Accord 0,75 mg/ml: Hver ml opløsning indeholder 0,75 mg eptifibatid. Et 
hætteglas med 100 ml infusionsvæske indeholder 75 mg eptifibatid. </li>
<li>Øvrige indholdsstoffer: citronsyre, natriumhydroxid og vand til injektionsvæske. </li>
</ul>
<p>Udseende og pakningstørrelser 
Eptifibatide Accord 0,75 mg/ml infusionsvæske, opløsning: 100 ml hætteglas, pakning med 1 hætteglas.  </p>
<p>Eptifibatide Accord 0,75 mg/ml: Klar, farveløs opløsning i 100 ml hætteglas, lukket med 
butylgummiprop og forseglet med "flip-off"-aluminiumforsegling. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen: </p>
<p>Accord Healthcare S.L.U.<br />
World Trade Center, Moll de Barcelona, s/n,<br />
Edifici Est 6ª planta,<br />
08039 Barcelona,<br />
Spanien </p>
<p>Fremstiller: </p>
<p>Accord Healthcare Polska Sp.z o.o., 
ul. Lutomierska 50,95-200 Pabianice, Polen </p>
<p>Denne indlægsseddel blev senest ændret &lt;{MM/ÅÅÅÅ}. </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs<br />
http://www.ema.europa.eu </p>
<p>Indlægsseddel: Information til patienten </p>
<p>Eptifibatide Accord 2 mg/ml injektionsvæske, opløsning 
eptifibatid </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at få dette lægemiddel, da den indeholder 
vigtige oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er mere, du vil vide. 
- Kontakt lægen, apotekspersonalet eller sygeplejersken, hvis en bivirkning bliver værre, eller 
du får bivirkninger, som ikke er nævnt her. Se punkt 4. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-4e78538b495fe763304c16d92584575d
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for eptifibatide Package Leaflet for language en"
Description: "ePI document Bundle for eptifibatide Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-4e78538b495fe763304c16d92584575d"
* entry[0].resource = composition-en-4e78538b495fe763304c16d92584575d

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4e78538b495fe763304c16d92584575d"
* entry[=].resource = mp4e78538b495fe763304c16d92584575d
                            
                    
Instance: bundlepackageleaflet-da-4e78538b495fe763304c16d92584575d
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for eptifibatide Package Leaflet for language da"
Description: "ePI document Bundle for eptifibatide Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-4e78538b495fe763304c16d92584575d"
* entry[0].resource = composition-da-4e78538b495fe763304c16d92584575d

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4e78538b495fe763304c16d92584575d"
* entry[=].resource = mp4e78538b495fe763304c16d92584575d
                            
                    



Instance: mp4e78538b495fe763304c16d92584575d
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product eptifibatide"
Description: "eptifibatide"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "14"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin."


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "eptifibatide"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 4e78538b495fe763304c16d92584575dListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "eptifibatide"

* status = #current
* mode = #working

* title = "List of all ePIs associated with eptifibatide"

* subject = Reference(mp6800cbc006aecb209b34dd0d22d9e8db)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#eptifibatide "eptifibatide"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-4e78538b495fe763304c16d92584575d) // eptifibatide en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-4e78538b495fe763304c16d92584575d) // eptifibatide da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-4e78538b495fe763304c16d92584575d
InstanceOf: List

* insert 4e78538b495fe763304c16d92584575dListRuleset
    